You searched for "tarsal"

721 results found

Ultrasound imaging of the eyes

Since its initial use in the eyes fifty years ago, ultrasound has established itself as a common diagnostic technique in ophthalmology. Sonographers, engineers and clinicians from all around the world have contributed to the development of ocular ultrasonography. As a...

The influence of refraction correction in swept source AS-OCT measurement parameters

Anterior segment (AS) optical coherence tomography (OCT) is the non-invasive technique used to analyse detailed cross-sectional images of the anterior structures of the eye. Swept source (SS) OCT at 1310nm can penetrate deeply into the eye with low levels of...

Eye research: where next?

Eye research in the UK is underfunded relative to other areas of medical research and general awareness of sight loss and its prevention remains poor, messages that were reinforced in presentations and discussions during a recent research summit meeting in...

A closer look at the new wave of glaucoma surgery – radical or old school?

Glaucoma is a challenging condition to treat because the exact pathophysiology remains unclear and the only readily modifiable factor is the intraocular pressure (IOP). Additionally, most glaucoma patients are completely asymptomatic, yet are often subjected to lifelong medical therapy. The...

Cutting-edge practice in glaucoma care: what, how and why?

More effective treatments and drug delivery modalities, implantable minimally invasive glaucoma surgical (MIGS) devices, as well as accelerating clinical research programmes, will transform the surgical and clinical management of glaucoma in the near future. There is also an ever-greater emphasis...

Clinical and management strategies in glaucoma practice: perspectives from international glaucoma specialists

Management options and outcomes in glaucoma practice were reviewed at the 7th Moorfields International Glaucoma Symposium, held in London on 24 January 2015. This article summarises perspectives from international glaucoma specialists on debated issues in topical therapy, glaucoma surgery, diagnostic...

Treatment of diabetic macular oedema

Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...

Personalising the management of dry eye disease: TFOS DEWS III updates evidence-based recommendations

Dry eye disease (DED) is a heterogenous condition that arises from various aetiologic factors and leads to tear film instability, ocular surface damage and neurosensory changes. Symptoms of DED include ocular dryness, burning, itching, pain and visual impairment. An evidence-based...

Report: UKEGS 2024

It was an incredible experience heading down to UKEGS 2024 earlier this month in Southampton. The entire Glaucoma UK team, along with the UKEGS overseeing panel Nishani Amerasinghe, Andrew Tatham, Professir Anthony King and Professor Gus Gazzard, took great care...

Glaucoma-NET: a novel way of improving glaucoma management in sub-Saharan Africa

Background Glaucoma is the second most common cause of blindness worldwide [1]. People with untreated glaucoma suffer from irreversible, progressive loss of sight. The disease is characterised by progressive loss of visual field, with pathological cupping of the optic disc...

Stem cell therapy for Parkinson’s disease: researching for an 
effective cure

Neurodegenerative diseases are characterised by the chronic and progressive loss of neurons, which in turn results in loss of cognitive and physical functions. The World Health Organization has estimated that the disability-adjusted life years lost from neurological disease was about...

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...